Day: November 6, 2020

— Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the Prednisone Group —MOUNTAIN VIEW, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that ACR Convergence 2020 — the virtual annual meeting of the American College of Rheumatology — will feature a plenary session presentation today on the ADVOCATE Phase III trial results of the Company’s lead drug candidate avacopan, an orally administered complement 5a receptor inhibitor, in the treatment of ANCA-associated vasculitis. A New Drug Application (NDA) for avacopan in ANCA-associated vasculitis is under review by the U.S. Food and Drug Administration.The Effect on Renal Function of the Complement C5a Receptor...

SANTA BARBARA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that members of management are scheduled to participate in four upcoming virtual investor conferences. The Company will participate in fireside chats at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 and the Stephens Annual Investment Conference 2020 on Friday, November 20, 2020.Event: Stifel 2020 Virtual Healthcare ConferenceFormat: Fireside Chat and 1×1 MeetingsDate: Monday, November 16, 2020Time: 6:20 a.m. PT / 9:20 a.m. ETEvent: 11thAnnual Craig-Hallum Alpha Select ConferenceFormat: 1×1 MeetingsDate: Tuesday, November 17, 2020Event: Canaccord Genuity Virtual MedTech & Diagnostics ForumFormat: 1×1 MeetingsDate:...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:Cowen 2020 Next IO SummitFriday, November 13, 2020Fireside Chat time: 2:45 p.m. ESTStifel 2020 Virtual Healthcare ConferenceWednesday, November 18, 2020Fireside Chat time: 4:40 p.m. ESTEvercore ISI 3rd Annual HealthCONxWednesday, December 2, 2020Panel Discussion time: 10:30 a.m. ESTTitle: “Finders Keepers: Identifying New Cancer Targets”Live audio webcasts of the Cowen and Stifel presentations can be accessed through the Events & Presentations section of the company’s...

Not for distribution to United States newswire services or for dissemination in the United States.VANCOUVER, British Columbia, Nov. 06, 2020 (GLOBE NEWSWIRE) — Deer Horn Capital Inc. (CSE: DHC) (the “Company” or “Deer Horn”), announces that is has closed the first tranche (the “First Tranche”) of its non-brokered private placement (the “Offering”) previously announced on October 14, 2020. Under the First Tranche, the Company has issued 1,600,000 units for gross proceeds of $80,000. No commissions or finder’s fees were paid in connection with the First Tranche closing.All securities issued under this First Tranche closing are subject to a hold period expiring March 6, 2021, in accordance with applicable securities laws and the policies of the CSE.Deer Horn also issued 1,000,000 units to settle debt of $50,000 owed to Docherty Capital...

In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021.SCYNEXIS estimates that there are over 15 million antifungal prescriptions written each year for the treatment of VVC.Enrollment is ongoing in the Phase 3 CANDLE study of oral ibrexafungerp for the prevention of recurrent vaginal yeast infections; top-line results and a second NDA submission anticipated in the second half of 2021.Enrollment continues in clinical studies of oral ibrexafungerp for the treatment of serious and life-threatening fungal infections, including those caused by drug-resistant Candida auris, recognized by the CDC as an urgent threat to public health.JERSEY CITY, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology...

KENNETT SQUARE, Pa., Nov. 06, 2020 (GLOBE NEWSWIRE) — Genesis HealthCare (NYSE:GEN) (Genesis or the Company), one of the nation’s largest providers of post-acute care, today announced that it expects to release its third quarter ended September 30, 2020 results before the market opens on Monday, November 9, 2020. A conference call and webcast will also be held on Monday, November 9, 2020 at 8:30 a.m. Eastern Time to discuss the results. To participate in the call, interested parties may dial (855) 849-2198 or listen to a live webcast and replay of the call on the Company’s website at http://www.genesishcc.com/investor-relations.About Genesis HealthCareGenesis HealthCare (NYSE: GEN) is a holding company with subsidiaries that, on a combined basis, comprise one of the nation’s largest post-acute care companies providing services...

100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to dateComplete response observed in seven of eight responding patientsEQUATE Phase 1b topline data expected during first half 2021LA JOLLA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease (aGVHD). The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids, as no other therapeutics are currently approved for this indication....

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021– Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets– Ongoing evaluations to expand pipeline beyond macimorelin opportunity– Cash runway to fund operations and expected to provide significant optionality for growthCHARLESTON, S.C., Nov. 06, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today reported its financial and operating results for the third quarter ended September 30, 2020.The Company also provided an update on its clinical program to expand the use of macimorelin for the diagnosis of childhood-onset...

Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegalyCRN04777 received Rare Pediatric Disease Designation for the treatment of congenital hyperinsulinismSAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.“Crinetics made significant progress in the third quarter, and we are excited by the recently reported positive topline ACROBAT Edge results showing that the study met its primary endpoint,” said Scott Struthers, Ph.D., Founder...

TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” or the “Company”) announces that it has provided a redemption notice to the holders of all outstanding Series B 7% Debentures of the Company due on June 30, 2021 pursuant to the terms of the amended and restated debenture indenture dated as of December 8, 2016 between the Company, the Guarantors (as defined in the Indenture) and Computershare Trust Company of Canada (the “Trustee”), as amended (collectively, the “Indenture“).Pursuant to the notice, the total outstanding principal amount of the debentures, being $5,087,590, will be redeemed effective as of December 6, 2020 (the “Redemption Date”) upon payment of a redemption amount of $1,050 for each $1,000 principal amount of Debentures plus all accrued and...